Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice

H. T. Wu, C. T. Chen, K. C. Cheng, Y. X. Li, C. H. Yeh, J. T. Cheng

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The mechanisms regarding hepatic steatosis related to hepatic insulin resistance have been well documented. However, the agents for treatment of hepatic steatosis and insulin resistance remain poorly developed. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that are responsible for the regulation of glucose and/or lipid metabolism. There are 3 distinct isoforms of PPARs family: PPAR, PPAR, and PPAR. Both PPAR and PPAR agonists are widely used in clinic for the treatment of hyperlipidemia and hyperglycemia. However, the therapeutic efficacy of PPAR agonists for diabetic disorders remains obscure. In the present study, we used L-165041as PPAR agonist to treat the high fat diet (HFD) fed mice. Administration of L-165041 improved the hepatic steatosis and increased the insulin sensitivity in HFD-mice. In addition to the histological identification of hepatic steatosis, the improvement of insulin sensitivity was characterized by the enhanced insulin signals and the increase of hepatic glycogen content. This is the first report showing that pharmacological activation of PPAR improves insulin resistance in diet-induced diabetic mice. Thus, we suggest that pharmacological activation of PPAR may be a new strategy for the treatment of diabetic patients with hepatic steatosis.

Original languageEnglish
Pages (from-to)631-635
Number of pages5
JournalHormone and Metabolic Research
Volume43
Issue number9
DOIs
Publication statusPublished - Jul 4 2011
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
High Fat Diet
Nutrition
Insulin Resistance
Chemical activation
Fats
Pharmacology
Insulin
Liver
4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid
Diabetic Diet
Liver Glycogen
Therapeutics
Hyperlipidemias
Lipid Metabolism
Hyperglycemia
Protein Isoforms
Transcription Factors

Keywords

  • diabetes
  • hepatic steatosis
  • high fat diet
  • insulin resistance
  • peroxisome proliferator-activated receptor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice. / Wu, H. T.; Chen, C. T.; Cheng, K. C.; Li, Y. X.; Yeh, C. H.; Cheng, J. T.

In: Hormone and Metabolic Research, Vol. 43, No. 9, 04.07.2011, p. 631-635.

Research output: Contribution to journalArticle

@article{724d94de2bd64010953117407701dbcc,
title = "Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice",
abstract = "The mechanisms regarding hepatic steatosis related to hepatic insulin resistance have been well documented. However, the agents for treatment of hepatic steatosis and insulin resistance remain poorly developed. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that are responsible for the regulation of glucose and/or lipid metabolism. There are 3 distinct isoforms of PPARs family: PPAR, PPAR, and PPAR. Both PPAR and PPAR agonists are widely used in clinic for the treatment of hyperlipidemia and hyperglycemia. However, the therapeutic efficacy of PPAR agonists for diabetic disorders remains obscure. In the present study, we used L-165041as PPAR agonist to treat the high fat diet (HFD) fed mice. Administration of L-165041 improved the hepatic steatosis and increased the insulin sensitivity in HFD-mice. In addition to the histological identification of hepatic steatosis, the improvement of insulin sensitivity was characterized by the enhanced insulin signals and the increase of hepatic glycogen content. This is the first report showing that pharmacological activation of PPAR improves insulin resistance in diet-induced diabetic mice. Thus, we suggest that pharmacological activation of PPAR may be a new strategy for the treatment of diabetic patients with hepatic steatosis.",
keywords = "diabetes, hepatic steatosis, high fat diet, insulin resistance, peroxisome proliferator-activated receptor",
author = "Wu, {H. T.} and Chen, {C. T.} and Cheng, {K. C.} and Li, {Y. X.} and Yeh, {C. H.} and Cheng, {J. T.}",
year = "2011",
month = "7",
day = "4",
doi = "10.1055/s-0031-1280781",
language = "English",
volume = "43",
pages = "631--635",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "9",

}

TY - JOUR

T1 - Pharmacological activation of Peroxisome proliferator-activated receptor improves insulin resistance and hepatic steatosis in high fat diet-induced diabetic mice

AU - Wu, H. T.

AU - Chen, C. T.

AU - Cheng, K. C.

AU - Li, Y. X.

AU - Yeh, C. H.

AU - Cheng, J. T.

PY - 2011/7/4

Y1 - 2011/7/4

N2 - The mechanisms regarding hepatic steatosis related to hepatic insulin resistance have been well documented. However, the agents for treatment of hepatic steatosis and insulin resistance remain poorly developed. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that are responsible for the regulation of glucose and/or lipid metabolism. There are 3 distinct isoforms of PPARs family: PPAR, PPAR, and PPAR. Both PPAR and PPAR agonists are widely used in clinic for the treatment of hyperlipidemia and hyperglycemia. However, the therapeutic efficacy of PPAR agonists for diabetic disorders remains obscure. In the present study, we used L-165041as PPAR agonist to treat the high fat diet (HFD) fed mice. Administration of L-165041 improved the hepatic steatosis and increased the insulin sensitivity in HFD-mice. In addition to the histological identification of hepatic steatosis, the improvement of insulin sensitivity was characterized by the enhanced insulin signals and the increase of hepatic glycogen content. This is the first report showing that pharmacological activation of PPAR improves insulin resistance in diet-induced diabetic mice. Thus, we suggest that pharmacological activation of PPAR may be a new strategy for the treatment of diabetic patients with hepatic steatosis.

AB - The mechanisms regarding hepatic steatosis related to hepatic insulin resistance have been well documented. However, the agents for treatment of hepatic steatosis and insulin resistance remain poorly developed. Peroxisome proliferator-activated receptors (PPARs) are transcription factors that are responsible for the regulation of glucose and/or lipid metabolism. There are 3 distinct isoforms of PPARs family: PPAR, PPAR, and PPAR. Both PPAR and PPAR agonists are widely used in clinic for the treatment of hyperlipidemia and hyperglycemia. However, the therapeutic efficacy of PPAR agonists for diabetic disorders remains obscure. In the present study, we used L-165041as PPAR agonist to treat the high fat diet (HFD) fed mice. Administration of L-165041 improved the hepatic steatosis and increased the insulin sensitivity in HFD-mice. In addition to the histological identification of hepatic steatosis, the improvement of insulin sensitivity was characterized by the enhanced insulin signals and the increase of hepatic glycogen content. This is the first report showing that pharmacological activation of PPAR improves insulin resistance in diet-induced diabetic mice. Thus, we suggest that pharmacological activation of PPAR may be a new strategy for the treatment of diabetic patients with hepatic steatosis.

KW - diabetes

KW - hepatic steatosis

KW - high fat diet

KW - insulin resistance

KW - peroxisome proliferator-activated receptor

UR - http://www.scopus.com/inward/record.url?scp=80051795701&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051795701&partnerID=8YFLogxK

U2 - 10.1055/s-0031-1280781

DO - 10.1055/s-0031-1280781

M3 - Article

VL - 43

SP - 631

EP - 635

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 9

ER -